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A substantial number of clinical studies have consistently demonstrated that low-molecular-
weight heparin (LMWH) compounds are effective and safe alternative anticoagulants to
unfractionated heparins (UFHs). They have been found to improve clinical outcomes in acute
coronary syndromes and to provide a more predictable therapeutic response, longer and more
stable anticoagulation, and a lower incidence of UFH-induced thrombocytopenia. Of the
several LMWH agents that have been studied in large clinical trials, including enoxaparin,
dalteparin, and nadroparin, not all have shown better efficacy than UFH. Enoxaparin is the
only LMWH compound to have demonstrated sustained clinical and economic benefits in
comparison with UFH in the management of unstable angina/ non–ST-segment elevation
myocardial infarction (NSTEMI). Also, LMWH appears to be a reliable and effective
antithrombotic treatment as adjunctive therapy in patients undergoing percutaneous coronary
intervention. Clinical trials with enoxaparin indicate that LMWH is effective and safe in this
indication, with or without the addition of a glycoprotein IIb/IIIa inhibitor. The efficacy
demonstrated by enoxaparin in improving clinical outcomes in unstable angina/NSTEMI
patients has led to investigations of its role in the management of ST-segment elevation
myocardial infarction. Initial results are very encouraging, and they indicate that enoxaparin
may potentially substitute for UFH as adjunctive therapy in fibrin-specific thrombolytic
regimens and improve coronary reperfusion rates in streptokinase-based regimens. (J Am
Coll Cardiol 2003;41:55S–61S) © 2003 by the American College of Cardiology Foundation
Acute coronary syndrome (ACS) refers to a constellation of
distinct clinical entities with a common etiology: an abrupt
imbalance between myocardial oxygen supply and demand
(i.e., myocardial ischemia) secondary to an acute plaque
disruption or erosion (1,2). The ST-segment elevation on the
presenting electrocardiogram indicates ST-segment elevation
myocardial infarction (STEMI) in the presence of abnormal
cardiac biomarkers, whereas patients who present without
ST-segment elevation are experiencing either unstable angina
(UA) or a non-STEMI (NSTEMI). The distinction between
these two diagnoses is ultimately made based on the presence
or absence of specific cardiac biomarkers such as troponin I or
T, or creatine kinase–myocardial band (1,2).
Disruption or erosion of atherosclerotic plaque exposes
oxidized low-density lipoprotein particles and tissue factor
to flowing blood, which activates the coagulation cascade (2)
(Fig. 1). This triggers platelet adhesion, aggregation and
fibrin deposition, the subsequent entrapment of red blood
cells, and ultimately the formation of a thrombus obstruct-
ing the coronary artery (1,2).
CURRENT MANAGEMENT OF ACS
The pharmacological treatment of ACS is designed to
prevent the progression of UA/NSTEMI to MI or death.
The optimal therapeutic approach currently recommended
by the American College of Cardiology/American Heart
Association guidelines includes a combination of antiplate-
let and antithrombotic therapy (2). These guidelines recom-
mend prompt initiation of aspirin (or a thienopyridine if
aspirin is not tolerated) and the addition of an anticoagulant
agent, such as unfractionated heparin (UFH) or low-
molecular-weight heparin (LMWH). A platelet glycopro-
tein (GP) IIb/IIIa receptor antagonist should be added if
ischemic pain continues (2), or in high-risk subjects. Clo-
pidogrel is also recommended for patients not going to
catheterization and bypass surgery (3).
LMWH VERSUS UFH
Although UFH was the standard anticoagulant, LMWH
constitutes an effective alternative antithrombotic therapy to
UFH, and it has a more favorable pharmacokinetic profile
and several clinical advantages (4). Both UFH and LMWH
act by binding to antithrombin III, an endogenous inhibitor
of Factors Xa and thrombin IIa. This binding induces a
conformational change in antithrombin 3, which markedly
accelerates its ability to inactivate these factors. The
LMWH compounds have a greater bioavailability than does
UFH, are more resistant to inhibition by activated platelets,
have a higher anti-Factor Xa:IIa activity ratio, and a more
predictable anticoagulant effect (4,5). Therefore, LMWH
can be administered subcutaneously in fixed doses, without
the need to monitor activated partial thromboplastin time
(aPTT) (5). In contrast, UFH usually requires intravenous
administration and constant monitoring and adjustment
of dosages (4). Moreover, LMWH is associated with a
lower incidence of adverse side effects compared to UFH,
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including heparin-induced thrombocytopenia and osteopo-
rosis (5).
A newer member of the LMWH family, fondaparinux, is
currently under clinical investigation. Fondaparinux is a
synthetic heparin pentasaccharide with selective anti-Factor
Xa activity (6). This compound displays a pharmacokinetic
profile comparable to LMWH, but with no anti-Factor IIa
activity.
Two LMWH compounds are Food and Drug Adminis-
tration–approved for the treatment of UA/NSTEMI: enox-
aparin (also approved for the treatment of venous throm-
bosis) and dalteparin. Other LMWH agents available
include tinzaparin (approved for the treatment of venous
thrombosis), nadroparin, and ardeparin (5). The LMWH
compounds have distinct properties that may translate into
differences in their clinical efficacy, and they are not inter-
changeable (7,8).
ROLE OF LMWH IN THE TREATMENT OF ACS
Two major double-blinded, randomized, placebo-controlled
trials have been conducted to assess the use of enoxaparin in
patients with UA/NSTEMI. The Efficacy and Safety of
Subcutaneous Enoxaparin in Non–Q-wave Coronary
Events (ESSENCE) trial randomized 3,171 patients to
receive either subcutaneous enoxaparin 1 mg/kg twice daily,
or UFH as a continuous IV infusion, both for two to eight
days (9). After 14 days, patients who had been treated with
enoxaparin had a significantly reduced risk of death, MI, or
recurrent angina compared to those who received UFH
(16.6% vs. 19.8%; p  0.019). This significant benefit was
sustained at 30 days (p  0.016). The incidence of major
bleeding complications was similar in both groups; an
increase in minor bleeding was observed with enoxaparin,
mainly attributable to ecchymoses at the injection site (9).
One-year follow-up results of the ESSENCE study
indicate that the significant reduction with enoxaparin in
the incidence of the composite end point was maintained
(32.0% vs. 35.7%; p  0.022) (10) (Fig. 2). Also, the need
for diagnostic catheterization and coronary revascularization
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tPA  tissue plasminogen activator
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Figure 1. The coagulation cascade. Interaction of the intrinsic pathway
(initiated by the activation of Factor XI) and the extrinsic pathway
(activated by vascular or tissue injury) results in a cascade of reactions that
generate thrombin (Factor IIa). Thrombin is produced from prothrombin
Factor II by the action of activated Factor X (Xa). Thrombin then acts on
fibrinogen to generate fibrin, which undergoes crosslinking, resulting in a
thrombin–fibrin clot.
Figure 2. ESSENCE study: One-year follow-up trial results. Significant
reductions were found in the composite end point of cardiovascular death,
myocardial infarction (MI), and recurrent angina with enoxaparin treat-
ment compared to treatment with unfractionated heparin (UFH). The
need for diagnostic catheterization and coronary revascularization was also
significantly reduced with enoxaparin treatment. ESSENCE, Efficacy and
Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events.
Reprinted with permission from the American College of Cardiology
Foundation, J Am Coll Cardiol 2000;36:693–8.
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was significantly reduced with enoxaparin compared to
UFH (55.8% vs. 59.4%, p  0.036, and 35.9% vs. 41.2%, p
 0.002, respectively) (10). A substudy of ESSENCE has
also shown that treatment with enoxaparin is more likely to
reduce rebound ischemia than UFH (11).
The Thrombolysis in Myocardial Infarction (TIMI)-11B
trial randomly assigned 3,910 UA/NSTEMI patients to
treatment with either enoxaparin or UFH for three to eight
days in an acute treatment phase (11). In the outpatient
phase, treatment with enoxaparin was continued for an
additional 35 days, and the UFH-treated group was
switched to placebo. At 14 days, there was a 15% reduction
in the composite end point of death, MI, or recurrent
angina with enoxaparin (14.2% vs. 16.7%; p  0.029). This
benefit was maintained at 43 days. However, long-term
treatment did not confer any additional reduction in death
and MI (12).
Interestingly, the TIMI-11B investigators have recently
shown that prior aspirin use in patients with UA/NSTEMI
is associated with a 60% higher risk of death and cardiac
ischemic events compared with nonprior aspirin users (13).
This subanalysis of ESSENCE and TIMI-11B demon-
strated that prior aspirin users treated with enoxaparin had
a reduced rate of death, MI, or urgent revascularization at
days 8 and 43 compared with prior aspirin users taking
UFH. In a prospectively planned meta-analysis of the
TIMI-11B and ESSENCE studies, a significant reduction
in the composite end point of death and MI with enoxapa-
rin compared to UFH was demonstrated at 43 days (7.1%
vs. 8.6%; p  0.02) (14). When recurrent angina leading to
urgent revascularization was included to form a triple,
composite end point, event rates were 15.6% versus 18.8%,
respectively (p  0.0005). A subgroup analysis of TIMI-
11B illustrated the variability associated with UFH in the
aPTT levels achieved (15), and that treatment with enox-
aparin provided better clinical outcomes for patients com-
pared with every level of anticoagulation with UFH. The
clinical superiority of enoxaparin in the management of
patients with NSTE ACS may be explained by its more
predictable anticoagulant effect (a characteristic of
LMWH). Indeed, it is difficult to maintain a target aPTT
level with UFH.
Cost-effectiveness. Pharmacoeconomic analyses based on
data from the ESSENCE study indicate that enoxaparin
may also represent a cost-effective alternative to UFH
(16–19). These analyses have shown that the beneficial
effects of enoxaparin translate into significant cost savings
(16–19). A recent study from the United Kingdom based on
the ESSENCE one-year data showed that the early eco-
nomic benefits of enoxaparin are also maintained in the
longer term (19).
The FRISC trials. The efficacy of dalteparin in the man-
agement of ACS has been evaluated in the FRagmin during
InStability in Coronary artery disease (FRISC) study. This
trial randomized 1,506 patients admitted with an ischemic
episode to either subcutaneous dalteparin 120 IU/kg twice
daily, or placebo, for six days, followed by continued
treatment with either placebo or a lower dose of dalteparin
(7,500 IU subcutaneously, once daily) for 35 to 45 days (19).
A significant benefit from treatment with dalteparin was
observed at six days. However, after 150 days, there was no
significant clinical benefit with dalteparin treatment.
In the FRISC II study, patients were randomized to either
dalteparin or placebo for three months, as well as to invasive or
noninvasive treatment. The combined end point of death and
MI was lower in the dalteparin-treated patients in the nonin-
vasive arm at one month, but not at three months or one year
in either the noninvasive or the invasive group (20,21).
The FRIC study. The FRagmin In unstable Coronary
artery disease (FRIC) trial compared the efficacy of dalte-
parin versus UFH in 1,482 UA/NSTEMI patients (22).
During the first six days of treatment, patients randomly
received either subcutaneous dalteparin or continuous IV
UFH infusion. Then, in a double-blind 45-day phase,
subjects received dalteparin 7,500 IU once daily or placebo.
The incidence of death, MI, or recurrent angina in the acute
phase was similar in the UFH and dalteparin groups (7.6%
vs. 9.3%; p  0.33). Prolonged (45-day) treatment with
dalteparin did not confer any additional benefit. A similar
incidence of major bleeding complications was observed in
both groups. These results suggest that treatment with
dalteparin is equivalent to treatment with UFH in patients
with UA/NSTEMI.
The FRAXIS study. The double-blinded, randomized
FRAXiparine in Ischemic Syndromes (FRAXIS) trial ex-
amined the efficacy of the LMWH nadroparin compared to
UFH in 3,468 patients with UA/NSTEMI. The effects of
acute-phase (6-day) treatment with UFH and nadroparin
(86 IU/kg) were compared, and the effect of an extended
(14-day) period of treatment with nadroparin (86 IU/kg)
was also evaluated (23). No significant differences existed in
clinical outcomes (cardiac death, MI, refractory angina, and
Figure 3. Meta-analysis of low-molecular-weight heparin (LMWH) trials
in unstable angina/non–ST-segment elevation myocardial infarction:
ESSENCE, Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-
wave Coronary Events; FRAXIS  FRAXiparine in Ischemic Syndromes;
FRIC  FRagmin In unstable Coronary artery disease; LMWH 
low-molecular-weight heparin; RRR  relative risk ratio; TIMI 
Thrombolysis in Myocardial Infarction; UFH  unfractionated heparin.
Adapted from Semin Thromb Hemost 1999;25 Suppl 3:113–21 (Fig. 3),
with permission from Thieme Publishers, 2002.
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recurrence of UA), but the incidence of major hemorrhage was
higher in the 14-day nadroparin group. The results of
FRAXIS indicate that nadroparin has a similar efficacy to
UFH in the treatment of ACS, but that a prolonged nadropa-
rin regimen does not offer any additional clinical benefit.
A meta-analysis of results from the four LMWH trials,
FRAXIS, FRIC, TIMI-11B, and ESSENCE, illustrates
the superiority of enoxaparin to UHF in the reduction of
primary end points (Fig. 3).
The PENTUA study. The PENTasaccharide in Unstable
Angina (PENTUA) study was a phase 2, randomized,
dose-ranging trial comparing fondaparinux to enoxaparin in
the treatment of 1,147 ACS patients with NSTEMI (24).
Four daily doses of subcutaneous fondaparinux were tested
(2.5, 4, 8, and 12 mg), as well as enoxaparin (administered
subcutaneously at 1 mg/kg twice daily). The mean treat-
ment duration was five days. The primary end point of
death, MI, and recurrent ischemia at day 9 occurred in 37%
of patients in the fondaparinux groups and in 40% in the
enoxaparin group. Patients receiving the lowest dose of
fondaparinux (2.5 mg) had the fewest primary end point
events at day 9 (30%), significantly lower than the enoxapa-
rin group and the groups receiving fondaparinux 4 and 8 mg
(p  0.05). The primary end point of death, MI, and
recurrent ischemia at day 30 was also lower, with the lowest
dose of fondaparinux (33.8%), compared to the enoxaparin
group (43.6%), and to the groups treated with fondaparinux
4, 8, and 12 mg (44.9%, 42.4%, 37.8%, respectively).
Bleeding rates were similarly low in all treatment groups.
No incidence of major bleeding occurred with the lowest
dose of fondaparinux or with enoxaparin. The results of
PENTUA indicate that fondaparinux is at least as effective
as enoxaparin in reducing the occurrence of thrombotic
events in ACS patients.
LMWH IN CORONARY INTERVENTION PROCEDURES
A number of randomized trials have demonstrated the
significant benefits of GP IIb/IIIa inhibitors in patients
undergoing percutaneous coronary intervention (PCI) (25).
By inhibiting the activity of GP IIb/IIIa receptors on the
platelet surface, GP IIb/IIIa inhibitors exert a direct anti-
aggregatory effect by preventing circulating fibrinogen from
interacting with platelet surfaces where it produces cross-
linkage of platelets, aggregation, and ultimately thrombus
formation (26–28). Because LMWH appears to offer sev-
eral pharmacological and practical advantages over UFH,
the safety and efficacy of LMWH, with or without GP
IIb/IIIA blockers, has been investigated in patients with
UA/NSTEMI who are candidates for PCI.
In a recent study (29), enoxaparin was administered
subcutaneously at 1 mg (100 IU)/kg every 12 h for at least
48 h to 451 ACS patients, 65% (n  213) of whom had a
coronary angiography within 8 h of enoxaparin administra-
tion, followed by immediate PCI (n  132; 28%). No
increase occurred in the rate of major bleeding in patients
undergoing PCI compared to those not undergoing cathe-
terization, and there were no incidences of abrupt closure or
urgent revascularization. The rate of death or MI at 30 days
was low (3% in the PCI group) compared to 6.2% in the
entire population, and to 10.8% in patients not undergoing
catheterization. This suggests that enoxaparin allows a safe
PCI without the need for additional anticoagulation in the
cardiac catheterization laboratory.
Further support for the efficacy of enoxaparin therapy in
PCI has been reported by the National Investigators Col-
laborating on Enoxaparin (NICE)-1 and -4 study groups
(30) (Fig. 4). The NICE studies revealed that treatment
with enoxaparin provided effective anticoagulation compa-
rable to that seen with weight-adjusted doses of UFH in
previous PCI trials (e.g., the Evaluation of Percutaneous
transluminal coronary angioplasty [PTCA] to Improve
Long-term Outcome by cF7E3 Glycoprotein receptor
blockade (EPILOG) trial and the Evaluation of Platelet
Inhibition in STENTing (EPISTENT) trial) (30–33).
Incidences of major and minor (nonintervention-related)
bleeding events associated with enoxaparin were low, and
they were not increased by the addition of abciximab. In the
NICE-3 study, which included patients treated with enox-
aparin in combination with either tirofiban, abciximab, or
eptifibatide, no statistically significant difference was ob-
served in the rates of nonintervention-related bleeding or
clinical event rates (Fig. 4).
A small (n  28) dose-finding trial investigating the
combination of dalteparin with abciximab during PCI (34)
found that dalteparin, given as an intravenous dose below 60
IU/kg with abciximab, resulted in catheter thrombosis (34).
Another small study (n 100) evaluated the potential for
locally administered LMWH to reduce restenosis after
coronary stent implantation. In the POlish-American local
LOvenox NIR Assessment (POLONIA) study, locally
delivered enoxaparin significantly reduced late luminal loss
compared to systemic heparinization (0.76  0.42 mm vs.
1.07  0.49 mm; p  0.001). Restenosis was also signifi-
Figure 4. Event rates with enoxaparin with or without glycoprotein
IIb/IIIa inhibitors in the NICE trials. MI  myocardial infarction;
NICE  National Investigators Collaborating on Enoxaparin; TVUR 
target vessel urgent revascularization. Kereiakes DJ, Grines C, Fry E.
Enoxaparin and abciximab adjunctive pharmacotherapy during percutane-
ous coronary intervention. J Invas Cardiol 2001;13:272–8. Printed with
permission from HMP Communications, 2002. Reprinted with permission
from the American College of Cardiology Foundation, J Am Coll Cardiol
2001;37 Suppl A:1A–648A; Abstract 1253–97.
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cantly reduced in the enoxaparin compared with the
systemic-heparin group (10% vs. 24%; p  0.05) (35).
LMWH AND GP IIB/IIIA
INHIBITORS IN NONINVASIVE PROCEDURES
A small study (n  55) compared the effects and safety of
UFH versus enoxaparin on the pharmacokinetics and phar-
macodynamics of tirofiban (36). In the enoxaparin–tirofiban
group, the degree of inhibition of platelet aggregation was
both greater and more predictable than in the UFH–
tirofiban group. Taking this factor into account, the ad-
justed bleeding time was 21% shorter among patients
receiving enoxaparin plus tirofiban (19.6 vs. 24.9 min; p 
0.02). Thus, the combination of tirofiban and enoxaparin
was safe and did not adversely affect the pharmacodynamics
of tirofiban, compared with UFH (36).
The Antithrombotic Combination Using Tirofiban and
Enoxaparin (ACUTE II) trial, a subsequent larger safety
study, assessed the safety of the combination of tirofiban
and enoxaparin (vs. UFH plus tirofiban) in 525 patients
with UA/NSTEMI (37). The primary safety end point was
the rate of TIMI bleeding to 24 h after study drug
completion (Fig. 5). Efficacy end points included death, MI,
rehospitalization for UA, and revascularization at 30 days.
No difference was found between the two groups in the rates
of major and minor TIMI bleeding, transfusion require-
ments, or clinical events, adding further support to the
safety of the LMWH–GP IIb/IIIa combination.
ROLE OF LMWH IN PATIENTS WITH STEMI
Antithrombotic therapy is a logical adjunct to thrombolytic
therapy in the early management of patients with STEMI.
Both the rate and the magnitude of coronary artery recan-
alization are increased and the risk of reocclusion is reduced,
resulting in improved clinical outcomes. The proven clinical
efficacy of enoxaparin in the management of NSTEMI has
led to the investigation of a role for enoxaparin in STEMI.
ANGIOGRAPHIC TRIALS
The Heparin and Aspirin Reperfusion Therapy (HART) II
trial (38) found a trend to improved effectiveness with the
immediate use of enoxaparin in conjunction with tissue
plasminogen activator (tPA) compared to UFH in achieving
infarct-related artery patency (TIMI-2 and -3 flow) 90 min
after the start of treatment. Patients in the enoxaparin group
had a significantly lower reocclusion rate at days five to
seven, with no increase in major bleeding.
The efficacy and safety of the synthetic heparin pentasac-
charide, fondaparinux, were assessed in the PENTALYSE
study in patients (n  333) with evolving STEMI (39).
Subjects were randomized to treatment with either intrave-
nous UFH during 48 to 72 h, or fondaparinux at dosages of
4 to 6 mg, 6 to 10 mg, or 10 to 12 mg daily for five to seven
days. Patients underwent coronary angiography at 90 min
and on days five to seven. Treatment with fondaparinux was
associated with a trend toward less reocclusion of the
infarct-related artery on days five to seven compared with
UFH (0.9% vs 7.0%; p  0.065) in patients who did not
undergo coronary intervention (n  155). During the
30-day follow-up period, fewer revascularization procedures
were performed in the fondaparinux group (39% vs. 51% for
UFH; p  0.054). Of the 241 patients in the fondaparinux
group, 1 (0.4%) had a nonfatal intracranial hemorrhage.
The study (39) indicates that fondaparinux given with
alteplase is safe and as effective as UFH in restoring
coronary artery patency in patients with STEMI.
CLINICAL OUTCOME TRIALS
The FRAgmin in acute Myocardial Infarction (FRAMI)
study and the BIOchemical Markers in Acute Coronary
Syndromes (BIOMACS) II study have shown trends indi-
cating that dalteparin may potentially improve clinical
outcomes when used as an adjunctive treatment to strep-
tokinase (40,41). However, in the FRAMI study, this
benefit was at the expense of increased bleeding risk. In
comparison, previous large trials evaluating the use of UFH
and streptokinase as combination therapy have not reported
improvements in clinical outcomes (42).
In the ASSENT PLUS study (43), dalteparin was com-
pared to UFH as adjunctive treatment to thrombolysis with
tPA. Dalteparin significantly reduced the occurrence of
reinfarction in patients with acute MI, compared to UFH.
Bleeding rates were similar.
The Acute Myocardial Infarction–StreptoKinase (AMI-
SK) study was recently conducted to evaluate the safety and
efficacy of enoxaparin versus placebo in patients receiving
streptokinase (44). The AMI-SK trial included 496 MI
patients who were randomized to treatment with either
enoxaparin (30 mg intravenous bolus followed by a subcu-
taneous dose of 1 mg/kg every 12 h) or placebos. The
TIMI-3 flow at 5 to 10 days was significantly improved in
the enoxaparin group (p  0.01), as was the combined
TIMI-2/3 flow (p  0.001), leading to a significant reduc-
Figure 5. Clinical event rates in ACUTE II trial. ACUTE  Antithrom-
botic Combination Using Tirofiban and Enoxaparin; enox  enoxaparin;
MI  myocardial infarction; TIMI  Thrombolysis in Myocardial
Infarction; tiro tirofiban. Cohen M. Anti-thrombotic combination using
tirofiban and enoxaparin: the ACUTE II study. Circulation 2000;102:II-
826. Reproduced with permission from Lippincott, Williams and Wilkins.
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tion in clinical ischemic events, without a significant in-
crease in bleeding.
The Assessment of the Safety and Efficacy of a New
Thrombolytic (ASSENT)-3 trial (45) compared the fi-
brinolytic agent tenecteplase, combined with enoxaparin or
abciximab, with tenecteplase plus UFH. Patients (n 
6,095) were randomized within 6 h of the onset of an acute
MI to single-bolus tenecteplase plus subcutaneous enoxapa-
rin, tenecteplase plus UFH (48-h infusion adjusted to
maintain aPTT between 50 to 70 s), or half-dose tenect-
eplase plus IV UFH and IV abciximab. The combined end
point of 30-day mortality, in-hospital reinfarction, or re-
fractory ischemia was significantly lower in the enoxaparin
and abciximab groups (11.4% and 11.1%, respectively; p 
0.0001) than in the UFH group (15.4%) (45). The efficacy
and safety end point (30-day mortality, in-hospital reinfarc-
tion, or refractory ischemia, intracranial hemorrhage, or
other major bleeding) also occurred less frequently (p 
0.0081) in the enoxaparin and abciximab groups (13.8% and
14.2%, respectively) compared to the UFH group (17.0%).
Results of the ASSENT-3 trial suggest that the combina-
tion of full-dose tenecteplase and up to seven-day admin-
istration of enoxaparin would be the best treatment for
patients with acute MI of  6 h.
ONGOING STUDIES WITH LMWH
Several trials have been undertaken to optimize reperfusion
therapy in STEMI and to evaluate the potential benefit of
triple-combination therapy with a GP IIb/IIIa inhibitor.
One such study, the ENoxaparin plus Tenecteplase-tPA
wIth/without GP IIb/IIIa as REperfusion for STEMI study
(ENTIRE), is evaluating the use of enoxaparin with abcix-
imab and tenecteplase.
Many patients do not receive any reperfusion therapy
because they present too late, or have significant contrain-
dications (46). The ongoing TETAMI study (47) is inves-
tigating the effect of enoxaparin versus UFH, with or
without tirofiban, on the outcome of patients who are not
candidates for thrombolytic therapy or PCI. The ongoing
multinational Superior Yield of the New strategy of Enox-
aparin, Revascularization & GlYcoprotein IIb/IIIa inhibi-
tors (SYNERGY) trial has enrolled over 8,000 patients in
over 400 centers. Its goal is to evaluate the efficacy and safety
of enoxaparin versus UFH as first-line management in
higher-risk NSTE ACS patients who are likely to also
receive treatment with GP IIb/IIIa (eptifibatide) and un-
dergo immediate catheterization and, if necessary, revascu-
larization. The clinical end points of the trial are death, MI,
major and minor hemorrhage, and all incidents of bleeding.
Reprint requests and correspondence: Dr. Marc Cohen, Divi-
sion of Cardiology, Newark Beth Israel Medical Center, 201
Lyons Avenue, Newark, New Jersey 07112. E-mail: marc.cohen@
sbhcs.com.
REFERENCES
1. Antman EM, Braunwald E. Acute myocardial infarction. In: Braun-
wald E, editor. Heart Disease: A Textbook of Cardiovascular Medi-
cine, 5th ed. Philadelphia: W.B. Saunders, 1997:1184–288.
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines
for the management of patients with unstable angina and non-ST-
segment elevation myocardial infarction. A report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on the Management of Patients With
Unstable Angina). J Am Coll Cardiol 2000;36:970–1062.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines
for the management of patients with unstable angina and non-ST-
segment elevation myocardial infarction. A report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on the Management of Patients With
Unstable Angina). J Am Coll Cardiol 2000;36:970–1062. (2002
Guideline Update, American College of Cardiology Web site. Avail-
able at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.
Accessed May 28, 2002.)
4. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-
weight heparin. Mechanism of action, pharmacokinetics, dosing con-
siderations, monitoring, efficacy, and safety. Chest 1998;114 Suppl
5:489S–510S.
5. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:
688–98.
6. Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for
the prevention of deep-vein thrombosis after total hip replacement.
N Engl J Med 2001;344:619–25.
7. Turpie AGG. Can we differentiate the low-molecular-weight hepa-
rins? Clin Cardiol 2000;23 Suppl I:I4–I7.
8. Nightingale SL. From the Food and Drug Administration. JAMA
1993;270:1672.
9. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low
molecular weight heparin with unfractionated heparin for unstable
coronary artery disease. Efficacy and Safety of Subcutaneous Enoxapa-
rin in Non-Q-wave Coronary Events Study Group. N Engl J Med
1997;337:447–52.
10. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low
molecular weight heparin (enoxaparin) versus unfractionated heparin
for unstable coronary artery disease: one-year results of the ESSENCE
study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-
Wave Coronary Events. J Am Coll Cardiol 2000;36:693–8.
11. Goodman SG, Barr A, Sobtchouck A, et al. Low molecular weight
heparin decreases rebound ischemia in unstable angina or non-Q-wave
myocardial infarction: the Canadian ESSENCE ST-segment moni-
toring substudy. J Am Coll Cardiol 2000;36:1507–13.
12. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents
death and cardiac ischaemic events in unstable angina/non-Q-wave
myocardial infarction. Results of the Thrombolysis in Myocardial
Infarction (TIMI)-11B trial. Circulation 1999;100:1593–601.
13. Santopinto J, Gurfinkel EP, Torres V, et al. Prior aspirin users with
acute non-ST elevation coronary syndromes are at increased risk of cardiac
events and benefit from enoxaparin. Am Heart J 2001;141:566–72.
14. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment
effect of enoxaparin for unstable angina/non-Q-wave myocardial
infarction. TIMI-11B-ESSENCE meta-analysis. Circulation 1999;
100:1602–8.
15. Bozovich GE, Gurfinkel EP, Antman EM, et al. Superiority of
enoxaparin versus unfractionated heparin for unstable angina/non-Q-
wave myocardial infarction regardless of activated partial thromboplas-
tin time. Am Heart J 2000;140:637–42.
16. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of
low molecular weight heparin (enoxaparin) versus unfractionated
heparin in acute coronary syndrome patients. Results from the ES-
SENCE randomised trial. Circulation 1998;97:1702–7.
17. Balen RM, Marra CA, Zed PJ. Cost-effectiveness analysis of enox-
aparin versus unfractionated heparin for acute coronary syndromes. A
Canadian hospital perspective. Pharmacoeconomics 1999;16:533–42.
18. Detournay B, Huet X, Fagani F, Montalescot G. Economic evaluation
of enoxaparin sodium versus heparin in unstable angina. A French
sub-study of the ESSENCE trial. Pharmacoeconomics 2000;18:83–9.
19. Bosanquet N, Fox KAA. Longer-term economic benefits reflect
improved clinical outcomes with enoxaparin versus unfractionated
60S Cohen JACC Vol. 41, No. 4 Suppl S
Managing Acute Coronary Syndromes February 19, 2003:55S–61S
heparin in acute coronary syndromes: one-year data. Br J Cardiol
2001;8:36–7.
20. Fragmin during Instability in Coronary Artery Disease (FRISC) Study
Group. Low molecular weight heparin during instability in coronary
artery disease. Lancet 1996;347:561–8.
21. Wallentin L, Lagerqvist B, Husted S, for the FRISC II Investigators.
Outcome at 1 year after an invasive compared to a non-invasive strategy
in unstable coronary artery disease: the FRISC II invasive randomised
trial. Lancet 2000;356:6–16.
22. Klein W, Buchwald A, Hillis SE, et al. Comparison of low molecular
weight heparin with unfractionated heparin acutely and with placebo
for 6 weeks in the management of unstable coronary artery disease.
Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circu-
lation 1997;96:61–8.
23. The FRAXIS Study Group. Comparison of two treatment durations
(6 days and 14 days) of a low molecular weight heparin with a 6-day
treatment of unfractionated heparin in the initial management of unstable
angina or non-Q-wave myocardial infarction: FRAXIS (Fraxiparine in
Acute Ischaemic Syndrome). Eur Heart J 1999;20:1553–62.
24. Simoons ML. The PENTUA study. Double-blind dose-ranging study
of fondaparinux (pentasaccharide) in unstable angina. Presented at the
American Heart Association Scientific Sessions, November 14, 2001.
Anaheim, California.
25. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of
therapeutic agents that block platelet glycoprotein IIb/IIIa integrin in
ischemic heart disease. Circulation 1998;98:2829–35.
26. Foster RH, Wiseman LR. Abciximab. An updated review of its use in
ischaemic heart disease. Drugs 1998;56:629–65.
27. McClellan KJ, Goa KL. Tirofiban: a review of its use in acute coronary
syndromes. Drugs 1998;56:1067–80.
28. Goa KL, Noble S. Eptifibatide: a review of its use in patients with
acute coronary syndromes and/or undergoing percutaneous coronary
intervention. Drugs 1999;57:439–62.
29. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary
intervention after subcutaneous enoxaparin pre-treatment in patients
with unstable angina pectoris. Circulation 2001;103:658–63.
30. Kereiakes DJ, Grines C, Fry E. Enoxaparin and abciximab adjunctive
pharmacotherapy during percutaneous coronary intervention. J Inva-
sive Cardiol 2001;13:272–8.
31. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous coronary revas-
cularization. N Engl J Med 1997;336:1689–96.
32. The EPISTENT Investigators. Randomised placebo-controlled and
balloon-angioplasty-controlled trial to assess safety of coronary stent-
ing with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;
352:87–92.
33. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intrave-
nous enoxaparin for percutaneous coronary intervention in stable
angina pectoris. Am J Cardiol 1999;84:1391–5.
34. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination
with abciximab during percutaneous coronary intervention. Am
Heart J 2001;141:348–52.
35. Kiesz RS, Buszman P, Martin JL, et al. Local delivery of enoxaparin
to decrease restenosis after stenting: results of initial multicenter trial:
Polish-American local Lovenox NIR assessment study (the POLO-
NIA study). Circulation 2001;103:26–31.
36. Cohen M, Theroux P, Weber S, et al. Combination therapy with
tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol
1999;71:273–81.
37. Cohen M. Anti-thrombotic combination using tirofiban and enoxapa-
rin: the ACUTE II study. Circulation 2000;102:II–826.
38. Ross AM, Molhoek P, Lundergaan C, et al. Randomised comparison
of enoxaparin, a low-molecular-weight heparin, with unfractionated
heparin adjunctive to recombinant tissue plasminogen activator throm-
bolysis and aspirin. Second trial of Heparin and Aspirin Reperfusion
Therapy (HART II). Circulation 2001;104:648–52.
39. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa
inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute
myocardial infarction. The PENTALYSE study. Eur Heart J 2001;
22:1716–24.
40. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low
molecular weight heparin (dalteparin) in prevention of left ventricular
thrombus formation and arterial embolism after acute anterior myo-
cardial infarction: the Fragmin in Acute Myocardial Infarction
(FRAMI) study. J Am Coll Cardiol 1997;30:962–9.
41. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight
heparin (dalteparin) as adjuvant treatment of thrombolysis in acute
myocardial infarction—a pilot study: biochemical markers in acute
coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627–
33.
42. Metz BK, White HD, Granger CB, et al. Randomized comparison of
direct thrombin inhibition versus heparin in conjunction with fibrino-
lytic therapy for acute myocardial infarction: results from the
GUSTO-IIb Trial. Global Use of Strategies to Open Occluded
Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb)
Investigators. J Am Coll Cardiol 1998;31:1493–8.
43. Wallentin L, Dellborg M, Lindahl B, et al. The low molecular weight
heparin dalteparin as adjuvant therapy in acute myocardial infarction:
the ASSENT PLUS study. Clin Cardiol 2001;24 Suppl 1:I12–I14.
44. Simoons ML, Krzemin˜ska-Pakula M, Alonso A, et al. Improved
reperfusion and clinical outcome with enoxaparin as an adjunct to
streptokinase thrombolysis in acute myocardial infarction. Lancet. In
Press.
45. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab, or unfractionated heparin:
the ASSENT-3 randomized trial in acute myocardial infarction.
Lancet 2001;358:605–13.
46. Rogers WJ, Canto JG, Barron HV, et al. Treatment and outcome of
myocardial infarction in hospitals with and without invasive capability.
Investigators in the National Registry of Myocardial Infarction. J Am
Coll Cardiol 2000;35:371–9.
47. Cohen M, Maritz F, Gensini GF, et al. The TETAMI trial: the safety
and efficacy of subcutaneous enoxaparin versus intravenous unfraction-
ated heparin and of tirofiban versus placebo in the treatment of acute
myocardial infarction for patients not thrombolyzed: methods and
design. J Thromb Thrombolysis 2000;10:241–6.
61SJACC Vol. 41, No. 4 Suppl S Cohen
February 19, 2003:55S–61S Managing Acute Coronary Syndromes
